

15 December 2022 EMA/CHMP/559891/2021 Committee for Medicinal Products for Human Use (CHMP)

Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product-specific bioequivalence guidance

Draft Agreed by Pharmacokinetics Working Party (PKWP)	21 March 2022
Adopted by CHMP for release for consultation 22 Apr	
Start of public consultation	17 May 2022
End of consultation (deadline for comments)	31 August 2022
Agreed by Pharmacokinetics Working Party	23 November 2022
Adopted by CHMP	15 December 2022
Date for coming into effect	1 July 2023

Keywords	Bioequivalence, generics, lanreotide acetate
----------	--



Lanreotide acetate, prolonged-release solution for injection in a prefilled syringe 60, 90 and 120 mg product-specific bioequivalence guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (PKWP)*

Bioequivalence study design

Single dose

Background: Taking into account the difficulties in performing a multiple dose study (e.g. 28 day dosing interval, multiple indications and limited target populations), as accumulation is not high and the single dose profile is captured over a prolonged period, a multiple dose study may be waived if the single dose PK is well characterised. Further analysis of the single dose data is therefore required to fully capture the pharmacokinetic profile.

Parallel design


Background: Due to the long half-life and for safety reasons the crossover design may not be practically feasible; therefore, a parallel design can be used.

Healthy volunteers

Strength: 120 mg

Background: highest strength to be used for a drug with linear pharmacokinetics.

	Other design aspects: The use of only one sex, e.g. males only or exactly the same number of male and female subjects in each treatment group, is recommended since sex differences are known to contribute to a high inter-subject variability for lanreotide. C_{max} has been found to be significantly higher in male than in female subjects and the rate of absorption was slower in female subjects.	
Analyte	□ parent □ metabolite □ both	
	□ plasma/serum □ blood □ urine	
	Enantioselective analytical method:	
Bioequivalence assessment	Main pharmacokinetic variables: AUC_{0-t} , $AUC_{0-\infty}$, C_{max} , C_{τ} (concentration at the end of the dosing interval, i.e. day 28), AUC_{0-168h} , $AUC_{168-672h}$ and AUC_{672h-t}	
	90% confidence interval: 80.00-125.00%	
Waiver of bioequivalence study	A waiver of in vivo bioequivalence studies may be granted if the test product has the same quantitative composition as the reference product and demonstrates equivalent molecular, structural, and thermodynamic properties as the reference product using a range of orthogonal techniques.	
	These studies could include:	
	• Molecular structure characterisation (peptide sequence): HRMS (High Resolution Mass Spectrometry) and NMR	
	Molecular scale organisation: FTIR spectroscopy & FT-Raman spectroscopy	
	• Supramolecular scale organisation (peptide folding): Freeze-fracture TEM, Small-Angle X-ray Scattering (SAXS) and Wide Angle X-ray Scattering (WAXS) or similar methods	
	Thermal stability: temperature-dependent SAXS.	



^{*} As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C_{max} . If high intra-individual variability ($CV_{intra} > 30\%$) is expected, the applicants might follow respective guideline recommendations.